The Effects of Trans-Resveratrol (RSV) on Insulin Resistance, Inflammation, and the Metabolic Syndrome: A Placebo Controlled, Double-Blind Study.
The metabolic syndrome is a serious health condition that affects about 35 percent of adults
and places them at higher risk of cardiovascular disease, diabetes, stroke and diseases
related to fatty buildups in artery walls. The underlying causes of metabolic syndrome are
obesity, being overweight, physical inactivity and genetic factors. In recent decades, the
prevalence has increased dramatically in the United States. Lifestyle interventions
including dietary modification, physical activity and weight loss form the basis of
treatment for these patients. However, research has shown that even when people are able to
incorporate these changes, they often revert back to their usual lifestyle resulting in
weight gain and continued risk for diabetes and heart disease.
Resveratrol, a natural plant derived compound found in grapes, peanuts and red wine, has
been found to reverse some of the features of the metabolic syndrome (insulin resistance,
high triglycerides, high blood pressure) in rodents. These improvements occurred without
weight loss, and were proven to be a direct result of resveratrol ingestion. Other studies
reveal improvement in cardiovascular health, tumor suppression, and longevity. However,
there are few studies investigating these beneficial effects in humans. In a systematic
review of resveratrol research, the authors conclude that "in contrast to the lacking data
of resveratrol in humans, the animal data are promising and indicate the need for further
human clinical trials." Of the small clinical studies that have been done, the results are
encouraging. Improvement in triglycerides, blood pressure and insulin resistance were noted.
Resveratrol was well tolerated without serious side effects. These studies, however, did not
recruit subjects with the metabolic syndrome, nor were they tightly controlled.
The investigators propose to prove that resveratrol, administered to subjects with the
metabolic syndrome, under controlled conditions of weight stability, common diet, and strict
compliance with the study drug, will improve the symptoms of the metabolic syndrome, thereby
decreasing the chance of developing diabetes or heart disease.
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Reduction in Insulin resistance
Investigators anticipate resveratrol will have positive effect (ie reduction) on Insulin resistance as determined by Euglycemic hyperinsulinemic clamp
Jeanne Walker, MSN/NP-C
The Rockefeller University
United States: Institutional Review Board
|The Rockefeller University||New York, New York 10065|